Threat Stack, provider of the industry’s most comprehensive intrusion detection platform for cloud, hybrid-cloud, and on-premise environments, today announced two major additions to its leadership team. Jonaki Egenolf has been named the company’s first Chief Marketing Officer, while Chris Ford joins as Vice President of Product.
Melinta Therapeutics Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced that concurrent with the closing of the merger, the board will add Jay Galeota, a pharmaceutical veteran who has held diverse key leadership positions including chief strategy and business development officer and president, emerging businesses at Merck & Co. Inc., and who is currently the president and chief operating officer of G&W Laboratories, Inc.
Interactions, LLC, a leading provider of Intelligent Virtual Assistants (IVAs) for enterprise customer care, today announced Robert Nagle has joined the company as Chief Technology Officer and Chief Product Officer.
Melinta Therapeutics, Inc., a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, and Cempra, Inc. (Nasdaq:CEMP) today announced that their joint chief executive officer (CEO) selection committee has selected Dan Wechsler to be president and CEO and a member of the board of directors of the combined company.
Colt has appointed Randy Nicklas, former CTO of XO Communications and then Windstream in the US, as its vice president of network engineering.
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the appointment of Richard Wenstrup, MD, as Chief Medical Officer.
Today Revolution Growth, Revolution’s growth-stage investment fund launched by Steve Case, Ted Leonsis, and Donn Davis, announced further expansion of its team following the closing of its $525 million Revolution Growth III fund last year. The changes include the addition of a new Partner, Todd Klein; the promotion of Steve Murray to Managing Partner and Evan Morgan to Special Partner; and the addition of Luisa Sucre as Analyst.
Sharief Taraman, MD, joins Cognoa as vice president of medical, bringing experience in pediatric neurology and leading Cognoa's healthcare and data science expansion.
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced the appointment of Donald Haut, Ph.D. as its Chief Business Officer.
NYU President Andrew Hamilton and Provost Katherine E. Fleming today named Neil Guterman, a nationally recognized expert on child abuse and neglect and child victimization, as dean of NYU's Silver School of Social Work, effective September 1, 2017.
Zymergen, Inc., a technology company focused on leveraging automation and computational tools to engineer microbes, has hired several new senior staff to lead and continue to develop the company’s research, development, and automation functions. These key additions are: David McLoughlin, Ph.D., Vice President of Automation; Jeff Touchman, Ph.D., Vice President of Metabolic Engineering; and Vytas SunSpiral, Director of Advanced Technology.
Mark Brodl, currently Associate Vice President for Academic Affairs: Budget and Research at Trinity University in San Antonio, Texas, has been named the next provost of Illinois Wesleyan University, effective July 17.
Data on executive target cash compensation for non-founders, from a 2016 survey of US-based private life sciences companies, reveal a 4.2% year-over-year rise following a 3.3% increase in 2015 and a 3% increase in 2014. The data points to consistent 'compensation inflation', according to CompStudy, which they believe more appropriately describes year-over-year movement.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the appointment of Christopher Wright, M.D., MMSc., Ph.D., as senior vice president of global development and chief development officer.
Morphew, now executive associate dean for research and innovation at the University of Iowa College of Education, will join Johns Hopkins on Aug. 1.
Merck & Co. has appointed Dean Y. Li, M.D., Ph.D. as Vice President, Head of Translational Medicine. Li most recently served as the H.A. & Edna Benning Professor of Medicine and Cardiology at the University of Utah, as the Vice-Dean of research at the University of Utah Health Science Center, and as the Chief Scientific Officer of University of Utah Health Care.
The University of Scranton’s 24th president, Rev. Scott R. Pilarz, S.J., ’H15 will return to Scranton to serve as the Jesuit University’s president again. Lawrence R. Lynch, chair of the University’s Board of Trustees, made the announcement to the University community today. Father Pilarz will succeed Kevin. P. Quinn, S.J., whose term as president ends in June at the close of the 2016-17 academic year.
Hofstra University President Stuart Rabinowitz announced the appointment of Dr. Benjamin Rifkin, professor of modern languages and literature at Ithaca College, as the new Dean of the Hofstra College of Liberal Arts & Sciences.
Thank you to those who participated in our February 3 CompStudy Technology and Life Sciences webinars: Executive Compensation & Team Composition: Attracting and Retaining the Best and Brightest to Your Team. Below you will find links to the presentation materials.
Linda Hall Library has appointed Jane Davis as Vice President for Access and Digital Services.
On January 11, 2017, more than 100 life sciences industry leaders outlined guiding principles and best practices to improve gender diversity throughout industry.
Denise Stephens, university librarian at the University of California, Santa Barbara (UCSB), has been appointed vice provost and university librarian at Washington University in St. Louis, effective July 1, according to Provost Holden Thorp. Stephens succeeds Jeffrey G. Trzeciak, who left the university last July.
The market for medical devices historically has been dominated by big-ticket “physician preference items” such as artificial joints, spinal implants, and cardiac pacemakers. Venture capital and private equity investors have been eager to fund new firms in this expanding and lucrative domain. Changes in physician payment and organization are reducing the demand for these cost-increasing innovations, however, and redirecting the flow of investment capital.